dapagliflozin/metformin (HCP1801)
/ Hanmi
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
July 14, 2022
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HCP1801 in Healthy Subjects
(clinicaltrials.gov)
- P1 | N=85 | Completed | Sponsor: Hanmi Pharmaceutical Company Limited | Unknown status ➔ Completed
Trial completion
1 to 1
Of
1
Go to page
1